---

---

publishing date : 2021 - 06 - 11    tags : Fda   

save search

---

FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions
Published: 2021-06-11 (Crawled : 18:17) - fda.gov
LLY | News | $742.04 1.46% 540K |

Health Technology

| Email alert Add to watchlist
fda fda approval cancer

---

FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer
Published: 2021-06-11 (Crawled : 18:03) - fda.gov
CLVS | $0.0812 -3.94% |

Health Technology

| -98.56% | O: 0.5% H: 0.33% C: -3.67%
approval fda granted cancer prostate cancer grant

---

FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%)
Published: 2021-06-11 (Crawled : 18:03) - fda.gov
A | $139.1 3.88% 790K |

Health Technology

| -6.4% | O: 0.21% H: 0.17% C: 0.12%
approval fda fda approval nivolumab

---

FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC
Published: 2021-06-11 (Crawled : 17:07) - fda.gov
LLY | News | $742.04 1.46% 540K |

Health Technology

| 213.15% | O: -2.79% H: 1.13% C: -1.29%
fda approval fda approval

---

FDA Takes Steps to Increase Availability of COVID-19 Vaccine
Published: 2021-06-11 (Crawled : 15:15) - fda.gov
JNJ | News | $149.575 0.31% 2.5M |

Health Technology

| -10.75% | O: -0.01% H: 0.01% C: -1.26%
covid fda vaccine covid-19

---

FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia
Published: 2021-06-11 (Crawled : 14:04) - fda.gov
ABBV | News | $170.19 1.37% 1.6M |

Health Technology

| 44.43% | O: 0.0% H: 0.1% C: -0.71%
fda granted approval leukemia myeloid leukemia grant acute myeloid leukemia

---

FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers
Published: 2021-06-11 (Crawled : 13:55) - fda.gov
CLVS | $0.0812 -3.94% |

Health Technology

| -98.56% | O: 0.5% H: 0.33% C: -3.67%
cancer test fda fda approval diagnostic biomarkers

---

FDA approves selinexor for refractory or relapsed multiple myeloma
Published: 2021-06-11 (Crawled : 13:47) - fda.gov
KPTI | $1.135 0.44% 300K |

Health Technology

| -89.29% | O: 1.61% H: 0.09% C: -3.73%
fda approval fda approval

---

FDA approves pralsetinib for RET-altered thyroid cancers
Published: 2021-06-11 (Crawled : 13:47) - fda.gov
BPMC | $92.38 1.95% 280K |

Health Technology

| 7.73% | O: 1.41% H: 2.24% C: 1.88%
cancer fda approval fda approval

---

FDA grants accelerated approval to naxitamab for high-risk neuroblastoma in bone or bone marrow
Published: 2021-06-11 (Crawled : 13:47) - fda.gov
YMAB | $16.145 6.5% 280K |

Health Technology

| -59.61% | O: 0.05% H: 1.54% C: -3.36%
risk fda granted approval grant

---

Sorrento Announces Clinical Research Agreement With Mayo Clinic and FDA Clearance for the First Phase 1b Pilot Study Using Sofusa Lymphatic Drug Delivery Technology to Deliver Ipilimumab in Patients With Melanoma
Published: 2021-06-11 (Crawled : 13:15) - globenewswire.com
SRNE | $0.015 140K |

Health Technology

| -99.89% | O: 0.92% H: 2.5% C: 0.68%
fda clearance fda phase 1 drug research technology drug delivery liver phase 1b clearance phase 2b

---

FDA approves cemiplimab-rwlc for non-small cell lung cancer with high PD-L1 expression
Published: 2021-06-11 (Crawled : 13:10) - fda.gov
REGN | News | $906.305 0.68% 87K |

Health Technology

| 69.19% | O: -0.52% H: 0.18% C: -0.7%
cancer fda fda approval

---

FDA approves tivozanib for relapsed or refractory advanced renal cell carcinoma
Published: 2021-06-11 (Crawled : 13:02) - fda.gov
AVEO | $15.0 0.0% 0 |

Health Technology

| 107.98% | O: -0.14% H: 0.42% C: 0.14%
fda fda approval cell carcinoma

---

FDA approves isatuximab-irfc for multiple myeloma
Published: 2021-06-11 (Crawled : 12:53) - fda.gov
SNY | News | $47.5 0.74% 450K |

Health Technology

| -13.96% | O: 0.13% H: 0.11% C: -0.09%
fda approval fda approval

---

FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma
Published: 2021-06-11 (Crawled : 12:43) - fda.gov
ADCT | $4.91 4.92% 150K |

Health Technology

| -78.94% | O: -0.18% H: 2.19% C: 0.14%
fda granted approval grant t-cell

---

FDA approves nivolumab for resected esophageal or GEJ cancer
Published: 2021-06-11 (Crawled : 12:24) - fda.gov
BMY | $49.2 0.12% 2.9M |

Health Technology

| -27.08% | O: 0.74% H: 0.07% C: -0.81%
cancer fda approval fda approval nivolumab

---

Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
INCY | $51.965 0.09% 590K |

Health Technology

| -40.68% | O: -3.27% H: 0.39% C: -2.47%
new drug treatment fda dermatitis drug atopic dermatitis application

---

Gainers vs Losers

87%

13%

Top 10 Gainers

MTTR | News M | $4.595 164.08% 13M |

AGBA | $2.355 88.4% 34M |

Finance

CZOO | $9.32 86.77% 18M |

EDBL | News | $6.75 79.52% 1.5M |

MTC | $2.28 46.15% 2.6M |

Technology Services

OPRT | News | $3.14 39.56% 7.6M |

Finance

VNRX | $0.8 33.33% 2.9M |

Health Technology

MLEC | $1.865 33.21% 2.4M |

n/a

PALI | $6.37 29.21% 21M |

Manufacturing

LOCL | $3.33 27.59% 43K |

---

Your saved searches

---